A randomized, double-blind, placebo-controlled evaluation of the efficacy of memantine on functional communication in patients with Alzheimer's disease.

Trial Profile

A randomized, double-blind, placebo-controlled evaluation of the efficacy of memantine on functional communication in patients with Alzheimer's disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2010

At a glance

  • Drugs Memantine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 28 Sep 2010 Clinical Global Impression results were presented at the 14th Congress of the European Federation of Neurological Societies.
    • 11 Jul 2010 Effects of memantine on global clinical status presented at the 2010 International Conference on Alzheimer's Disease.
    • 13 Sep 2009 Results presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top